

Kenneth G Saag

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/569405/publications.pdf>

Version: 2024-02-01

298
papers

29,806
citations

8755

75
h-index

5255

165
g-index

305
all docs

305
docs citations

305
times ranked

23119
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
2	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1-26.	5.6	1,880
3	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
4	The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2520-2526.	2.8	1,305
5	Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. <i>New England Journal of Medicine</i> , 1998, 339, 292-299.	27.0	1,192
6	Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. <i>New England Journal of Medicine</i> , 2017, 377, 1417-1427.	27.0	901
7	Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. <i>New England Journal of Medicine</i> , 2007, 357, 2028-2039.	27.0	806
8	Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women's Health Study. <i>Arthritis and Rheumatism</i> , 2004, 50, 72-77.	6.7	666
9	American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. <i>Arthritis Care and Research</i> , 2010, 62, 1515-1526.	3.4	633
10	Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. <i>New England Journal of Medicine</i> , 2018, 378, 1200-1210.	27.0	601
11	Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. <i>Arthritis and Rheumatism</i> , 2001, 44, 202-211.	6.7	485
12	Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events. <i>American Journal of Medicine</i> , 1994, 96, 115-123.	1.5	470
13	Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. <i>Lancet</i> , The, 2009, 373, 1253-1263.	13.7	452
14	Population-based assessment of adverse events associated with long-term glucocorticoid use. <i>Arthritis and Rheumatism</i> , 2006, 55, 420-426.	6.7	448
15	Obesity Is Not Protective against Fracture in Postmenopausal Women: GLOW. <i>American Journal of Medicine</i> , 2011, 124, 1043-1050.	1.5	446
16	Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. <i>Arthritis and Rheumatism</i> , 2009, 60, 3346-3355.	6.7	406
17	Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 285-293.	0.9	402
18	2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2557-2568.	5.6	393

#	ARTICLE	IF	CITATIONS
19	Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 267-272.	0.9	363
20	Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. <i>Arthritis and Rheumatism</i> , 2007, 56, 1125-1133.	6.7	351
21	The epidemiology of glucocorticoid-associated adverse events. <i>Current Opinion in Rheumatology</i> , 2008, 20, 131-137.	4.3	329
22	EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1560-1567.	0.9	325
23	Initiation of Tumor Necrosis Factor- α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2331-9.	7.4	305
24	Gout Medication Treatment Patterns and Adherence to Standards of Care From a Managed Care Perspective. <i>Mayo Clinic Proceedings</i> , 2006, 81, 925-934.	3.0	265
25	The clinician's guide to prevention and treatment of osteoporosis. <i>Osteoporosis International</i> , 2022, 33, 2049-2102.	3.1	255
26	Antioxidant Micronutrients and Risk of Rheumatoid Arthritis in a Cohort of Older Women. <i>American Journal of Epidemiology</i> , 2003, 157, 345-354.	3.4	221
27	Epidemiology, risk factors, and lifestyle modifications for gout. <i>Arthritis Research and Therapy</i> , 2006, 8, S2.	3.5	212
28	Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3785-3793.	3.6	205
29	Hip fracture trends in the United States, 2002 to 2015. <i>Osteoporosis International</i> , 2018, 29, 717-722.	3.1	198
30	Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women. <i>American Journal of Medicine</i> , 2002, 112, 465-471.	1.5	175
31	Treatment of rheumatoid arthritis. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 2451-2465.	1.0	170
32	Lesinurad Combined With Allopurinol: A Randomized, Double-blind, Placebo-controlled Study in Gout Patients With an Inadequate Response to Standard-of-care Allopurinol (a US-based Study). <i>Arthritis and Rheumatology</i> , 2017, 69, 203-212.	5.6	154
33	Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 445-454.	11.4	148
34	Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: Results from the Iowa Women's Health Study. <i>Arthritis and Rheumatism</i> , 2002, 46, 83-91.	6.7	147
35	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 36-52.	2.8	146
36	Fracture mortality: associations with epidemiology and osteoporosis treatment. <i>Nature Reviews Endocrinology</i> , 2014, 10, 592-602.	9.6	140

#	ARTICLE	IF	CITATIONS
37	Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). <i>Rheumatology</i> , 2005, 44, 1038-1042.	1.9	138
38	Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. <i>Arthritis and Rheumatology</i> , 2016, 68, 56-66.	5.6	136
39	Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2631-2637.	3.6	135
40	Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. <i>Arthritis and Rheumatism</i> , 2005, 52, 2485-2494.	6.7	133
41	ACTIVEExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2949-2957.	3.6	131
42	Quality of care indicators for gout management. <i>Arthritis and Rheumatism</i> , 2004, 50, 937-943.	6.7	130
43	Sex differences in gout epidemiology: evaluation and treatment. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1368-1372.	0.9	128
44	Glucocorticoid-induced osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2003, 32, 135-157.	3.2	125
45	Death, Debility, and Destitution Following Hip Fracture. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69A, 346-353.	3.6	125
46	Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. <i>Osteoporosis International</i> , 2008, 19, 1613-20.	3.1	121
47	Glucocorticoid-induced osteoporosis: 2019 concise clinical review. <i>Osteoporosis International</i> , 2019, 30, 1145-1156.	3.1	120
48	Longitudinal Trends in Use of Bone Mass Measurement Among Older Americans, 1999-2005. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1061-1067.	2.8	115
49	The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. <i>Osteoporosis International</i> , 2012, 23, 2141-2150.	3.1	112
50	Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. <i>Seminars in Arthritis and Rheumatism</i> , 2003, 33, 72-82.	3.4	106
51	Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study. <i>Osteoporosis International</i> , 2009, 20, 819-826.	3.1	104
52	Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1174-1184.	5.6	102
53	Population-Based Fracture Risk Assessment and Osteoporosis Treatment Disparities by Race and Gender. <i>Journal of General Internal Medicine</i> , 2009, 24, 956-962.	2.6	101
54	Benefit of Adherence With Bisphosphonates Depends on Age and Fracture Type: Results From an Analysis of 101,038 New Bisphosphonate Users. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1435-1441.	2.8	100

#	ARTICLE	IF	CITATIONS
55	Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAFETY Assessment of Biologic ThERapy (SABER) Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1942-1948.	0.9	100
56	The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1401-1406.	0.9	98
57	Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women. <i>Journal of Rheumatology</i> , 2002, 29, 246-54.	2.0	97
58	Measuring quality in arthritis care: Methods for developing the Arthritis Foundation's quality indicator set. <i>Arthritis and Rheumatism</i> , 2004, 51, 193-202.	6.7	95
59	Impact of Febuxostat on Renal Function in Gout Patients With Moderate to Severe Renal Impairment. <i>Arthritis and Rheumatology</i> , 2016, 68, 2035-2043.	5.6	95
60	Riloncept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. <i>Arthritis Care and Research</i> , 2012, 64, 1462-1470.	3.4	94
61	Glucocorticoid-induced Osteoporosis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 177-189.	1.9	93
62	The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA. <i>Osteoporosis International</i> , 2017, 28, 1225-1232.	3.1	92
63	Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 990-997.	3.4	90
64	Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1813-1818.	0.9	90
65	Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. <i>Rheumatology</i> , 2017, 56, 2170-2178.	1.9	90
66	Choosing wisely: The American College of Rheumatology's top 5 list of things physicians and patients should question. <i>Arthritis Care and Research</i> , 2013, 65, 329-339.	3.4	89
67	Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial. <i>Journal of Rheumatology</i> , 2009, 36, 1705-1714.	2.0	87
68	Improving the Prediction of Medication Compliance. <i>Medical Care</i> , 2009, 47, 334-341.	2.4	87
69	Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture. <i>Journal of Clinical Densitometry</i> , 2011, 14, 212-219.	1.2	85
70	Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2019, 21, 34.	4.7	85
71	Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 994-999.	0.9	83
72	Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. <i>Arthritis and Rheumatism</i> , 1996, 39, 1818-1825.	6.7	81

#	ARTICLE	IF	CITATIONS
73	The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. <i>Osteoporosis International</i> , 2009, 20, 1107-1116.	3.1	79
74	Health Care Expenditures Associated With Skeletal Fractures Among Medicare Beneficiaries, 1999â€“2005. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 2050-2055.	2.8	79
75	Failure to perceive increased risk of fracture in women 55Âyears and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>Osteoporosis International</i> , 2011, 22, 27-35.	3.1	79
76	Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1065-1071.	0.9	79
77	Challenges in Improving the Quality of Osteoporosis Care for Long-term Glucocorticoid Users. <i>Archives of Internal Medicine</i> , 2007, 167, 591.	3.8	78
78	Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>Bone</i> , 2011, 49, 493-498.	2.9	78
79	Drugâ€specific and timeâ€dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor Î± antagonists. <i>Arthritis and Rheumatism</i> , 2007, 56, 4226-4227.	6.7	76
80	From bone biology to clinical outcome: state of the art and future perspectives. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1415-1419.	0.9	76
81	Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapyâ€Induced Osteoporosis Treated With Alendronate or Teriparatide. <i>Arthritis and Rheumatology</i> , 2016, 68, 2122-2128.	5.6	76
82	Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). <i>Nature Reviews Rheumatology</i> , 2017, 13, 561-568.	8.0	74
83	Clinical and demographic factors associated with fractures among older Americans. <i>Osteoporosis International</i> , 2011, 22, 1263-1274.	3.1	73
84	Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian women. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1163-1167.	0.9	72
85	Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 321-327.e7.	5.0	72
86	Modifiable Factors Associated with Allopurinol Adherence and Outcomes Among Patients with Gout in an Integrated Healthcare System. <i>Journal of Rheumatology</i> , 2015, 42, 504-512.	2.0	69
87	Brief Report: Validation of a Definition of Flare in Patients With Established Gout. <i>Arthritis and Rheumatology</i> , 2018, 70, 462-467.	5.6	68
88	Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare data. <i>Osteoporosis International</i> , 2009, 20, 1507-1515.	3.1	67
89	Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an expertsâ€™ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. <i>Osteoporosis International</i> , 2019, 30, 45-57.	3.1	67
90	Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. <i>Osteoporosis International</i> , 2014, 25, 85-95.	3.1	66

#	ARTICLE	IF	CITATIONS
91	A REDCap-based model for electronic consent (eConsent): Moving toward a more personalized consent. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 345-353.	0.6	65
92	Serum urate and its relationship with alcoholic beverage intake in men and women: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1965-1970.	0.9	63
93	Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 924-928.	0.9	63
94	When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>PLoS ONE</i> , 2013, 8, e83306.	2.5	63
95	Identifying types of nursing facility stays using medicare claims data: an algorithm and validation. <i>Health Services and Outcomes Research Methodology</i> , 2010, 10, 100-110.	1.8	62
96	Racial Disparities in Osteoporosis Prevention in a Managed Care Population. <i>Southern Medical Journal</i> , 2003, 96, 445-451.	0.7	61
97	Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 710-718.	1.9	59
98	Is Withholding Osteoporosis Medication After Fracture Sometimes Rational? A Comparison of the Risk for Second Fracture Versus Death. <i>Journal of the American Medical Directors Association</i> , 2010, 11, 584-591.	2.5	57
99	Randomized Trial to Improve Fracture Prevention in Nursing Home Residents. <i>American Journal of Medicine</i> , 2007, 120, 886-892.	1.5	56
100	Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. <i>Bone</i> , 2012, 50, 289-295.	2.9	55
101	Glucocorticoid-induced osteoporosis update. <i>Current Opinion in Rheumatology</i> , 2019, 31, 388-393.	4.3	55
102	New insights into gout epidemiology. <i>Current Opinion in Rheumatology</i> , 2006, 18, 199-203.	4.3	52
103	Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?. <i>Arthritis Research and Therapy</i> , 2009, 11, 240.	3.5	52
104	Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab. <i>Arthritis and Rheumatology</i> , 2015, 67, 1456-1464.	5.6	51
105	Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2012, 64, 1480-1489.	3.4	49
106	Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial. <i>American Journal of Medicine</i> , 2019, 132, 354-361.	1.5	49
107	Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1012-1016.	0.9	48
108	Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?. <i>Arthritis and Rheumatism</i> , 2011, 63, 325-328.	6.7	47

#	ARTICLE	IF	CITATIONS
109	Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1881-1888.	2.8	47
110	Pathophysiology, Clinical Presentation and Treatment of Gout. <i>Drugs</i> , 2006, 66, 1547-1563.	10.9	46
111	A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. <i>Arthritis and Rheumatology</i> , 2021, 73, 1533-1542.	5.6	45
112	The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. <i>Rheumatology</i> , 2005, 44, 781-788.	1.9	44
113	Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence. <i>American Journal of Medicine</i> , 1997, 103, S31-S39.	1.5	43
114	The delivery of evidence-based preventive care for older Americans with arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R144.	3.5	43
115	Trends in prevention of glucocorticoid-induced osteoporosis. <i>Journal of Rheumatology</i> , 2006, 33, 1651-7.	2.0	43
116	Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. <i>Osteoporosis International</i> , 2006, 17, 1268-1274.	3.1	40
117	Glucocorticoids and the risk of osteoporosis. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 33-47.	2.4	40
118	Osteoporosis Care in the United States After Declines in Reimbursements for DXA. <i>Journal of Clinical Densitometry</i> , 2010, 13, 352-360.	1.2	40
119	Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data. <i>Journal of the National Medical Association</i> , 2005, 97, 1155-60.	0.8	40
120	Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. <i>Journal of Rheumatology</i> , 1995, 22, 2142-7.	2.0	40
121	Progress in osteoporosis and fracture prevention: focus on postmenopausal women. <i>Arthritis Research and Therapy</i> , 2009, 11, 251.	3.5	38
122	Understanding Preferences for Osteoporosis Information to Develop an Osteoporosis Patient Education Brochure. , 2017, 21, 16-024.		38
123	Defining quality of care in rheumatology: The American College of Rheumatology white paper on quality measurement. <i>Arthritis Care and Research</i> , 2011, 63, 2-9.	3.4	37
124	Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. <i>Hypertension</i> , 2020, 75, 246-256.	2.7	37
125	Glucocorticoid use in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2002, 4, 218-225.	4.7	36
126	RisedronatE and Alendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. <i>Osteoporosis International</i> , 2009, 20, 973-978.	3.1	35

#	ARTICLE	IF	CITATIONS
127	Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. <i>Journal of Clinical Densitometry</i> , 2021, 24, 3-13.	1.2	35
128	Developments in Glucocorticoid Therapy. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 1-17.	1.9	34
129	A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis study. <i>Contemporary Clinical Trials Communications</i> , 2016, 3, 32-38.	1.1	32
130	Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice-Based Network. <i>Arthritis Care and Research</i> , 2021, 73, 1153-1161.	3.4	32
131	Quality Indicators for the Care of Osteoarthritis in Vulnerable Elders. <i>Journal of the American Geriatrics Society</i> , 2007, 55, S383-91.	2.6	31
132	Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. <i>Bone</i> , 2010, 46, 929-934.	2.9	31
133	Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fracture. <i>Journal of Rheumatology</i> , 2005, 32, 870-5.	2.0	31
134	Bridging the Osteoporosis Quality Chasm. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 3-7.	2.8	30
135	Association of Early Postoperative Pain Trajectories With Longer-term Pain Outcome After Primary Total Knee Arthroplasty. <i>JAMA Network Open</i> , 2019, 2, e1915105.	5.9	30
136	Osteoporosis in 10 years time: a glimpse into the future of osteoporosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210835.	2.7	30
137	Preferences for Fractures and Other Glucocorticoid-Associated Adverse Effects among Rheumatoid Arthritis Patients. <i>Medical Decision Making</i> , 2001, 21, 122-132.	2.4	29
138	Racial/ethnic disparities in patient-reported nonsteroidal antiinflammatory drug (NSAID) risk awareness, patient-doctor NSAID risk communication, and NSAID risk behavior. <i>Arthritis and Rheumatism</i> , 2007, 57, 1539-1545.	6.7	29
139	Drug Insight: choosing a drug treatment strategy for women with osteoporosis—an evidence-based clinical perspective. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 240-248.	3.2	29
140	Health Literacy and Happiness: A Community-based Study. <i>Social Indicators Research</i> , 2010, 95, 325-338.	2.7	29
141	Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1466-1472.	2.8	29
142	SARS CoV-2 infection among patients using immunomodulatory therapies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 269-271.	0.9	29
143	Improving drug adherence in osteoporosis: an update on more recent studies. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2018, 10, 141-149.	2.7	28
144	Nonsteroidal Anti-Inflammatory Drugs and Cognitive Function. <i>Drug Safety</i> , 1998, 19, 427-433.	3.2	27

#	ARTICLE	IF	CITATIONS
145	Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 763-772.	2.8	27
146	The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs. <i>Arthritis and Rheumatism</i> , 2003, 49, 293-299.	6.7	26
147	OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout. <i>Journal of Rheumatology</i> , 2014, 41, 569-573.	2.0	26
148	Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. <i>Bone</i> , 2019, 123, 191-195.	2.9	26
149	Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2007, 7, 101-112.	5.7	24
150	The PAADRN Study: A design for a randomized controlled practical clinical trial to improve bone health. <i>Contemporary Clinical Trials</i> , 2013, 34, 90-100.	1.8	24
151	Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. <i>Current Opinion in Rheumatology</i> , 2008, 20, 320-326.	4.3	23
152	The Role of Health Literacy and Written Medicine Information in Nonsteroidal Antiinflammatory Drug Risk Awareness. <i>Annals of Pharmacotherapy</i> , 2010, 44, 274-284.	1.9	23
153	Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States. <i>Contemporary Clinical Trials</i> , 2012, 33, 1211-1216.	1.8	23
154	Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 386-392.	0.9	23
155	Efficacy and safety of febusostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. <i>Arthritis Research and Therapy</i> , 2018, 20, 99.	3.5	23
156	Comorbidities in gout and hyperuricemia: causality or epiphenomena?. <i>Current Opinion in Rheumatology</i> , 2020, 32, 126-133.	4.3	23
157	Quality health care gaps in osteoporosis: How can patients, providers, and the health system do a better job?. <i>Current Osteoporosis Reports</i> , 2009, 7, 27-34.	3.6	22
158	Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. <i>Osteoporosis International</i> , 2016, 27, 3513-3524.	3.1	22
159	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2016, 28, 1-16.	2.9	22
160	Importance of Recent Fracture as Predictor of Imminent Fracture Risk. <i>Current Osteoporosis Reports</i> , 2018, 16, 738-745.	3.6	22
161	Racial Disparities Exist in Outcomes After Major Fragility Fractures. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1803-1810.	2.6	22
162	Measuring quality in arthritis care: The Arthritis Foundation's quality indicator set for analgesics. <i>Arthritis and Rheumatism</i> , 2004, 51, 337-349.	6.7	21

#	ARTICLE	IF	CITATIONS
163	Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting System. <i>Arthritis Care and Research</i> , 2013, 65, 235-243.	3.4	21
164	Understanding practice-based research participation: The differing motivations of engaged vs. non-engaged clinicians in pragmatic clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2016, 4, 136-140.	1.1	21
165	Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis. <i>New England Journal of Medicine</i> , 2018, 378, 194-196.	27.0	21
166	Burosumab in tumor-induced osteomalacia: A case report. <i>Joint Bone Spine</i> , 2020, 87, 81-83.	1.6	21
167	Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study. <i>Arthritis Research and Therapy</i> , 2020, 22, 86.	3.5	21
168	Arthritis health service utilization among the elderly: The role of urban-rural residence and other utilization factors. <i>Arthritis and Rheumatism</i> , 1998, 11, 177-185.	6.7	20
169	Bisphosphonates and glucocorticoid-induced osteoporosis: cons. <i>Endocrine</i> , 2015, 49, 628-634.	2.3	20
170	Simulation-based power and sample size calculation for designing interrupted time series analyses of count outcomes in evaluation of health policy interventions. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100474.	1.1	20
171	Prevention of Glucocorticoid-induced Osteoporosis. <i>Southern Medical Journal</i> , 2004, 97, 555-558.	0.7	19
172	Prevention and treatment of glucocorticoid-induced osteoporosis. <i>Current Osteoporosis Reports</i> , 2007, 5, 14-21.	3.6	19
173	Osteopenia: Debates and Dilemmas. <i>Current Rheumatology Reports</i> , 2013, 15, 384.	4.7	19
174	Recent advances in the epidemiology of gout. <i>Current Rheumatology Reports</i> , 2005, 7, 235-241.	4.7	18
175	Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. <i>Osteoporosis International</i> , 2010, 21, 1573-1584.	3.1	18
176	Effect of Self-referral on Bone Mineral Density Testing and Osteoporosis Treatment. <i>Medical Care</i> , 2014, 52, 743-750.	2.4	18
177	Evaluating and mitigating fracture risk in established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 614-627.	3.3	18
178	Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 503-509.	1.5	18
179	Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1987646.	2.7	18
180	Practice Pattern Variation Among Internal Medicine Specialists in the Prevention of Glucocorticoid-Induced Osteoporosis. <i>Journal of Clinical Rheumatology</i> , 2000, 6, 117-122.	0.9	17

#	ARTICLE	IF	CITATIONS
181	Long-term Safety Concerns of Antiresorptive Therapy. <i>Rheumatic Disease Clinics of North America</i> , 2011, 37, 387-400.	1.9	17
182	An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis. <i>Osteoporosis International</i> , 2011, 22, 305-315.	3.1	17
183	Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. <i>Rheumatology</i> , 2019, 58, 61-69.	1.9	17
184	<p>Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy</p>. <i>Core Evidence</i> , 2019, Volume 14, 41-50.	4.7	17
185	Resolved: Low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001, 45, 468-471.	6.7	16
186	Improving bone mineral density reporting to patients with an illustration of personal fracture risk. <i>BMC Medical Informatics and Decision Making</i> , 2014, 14, 101.	3.0	16
187	Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 143-153.	5.6	16
188	Physical activity measured using wearable activity tracking devices associated with gout flares. <i>Arthritis Research and Therapy</i> , 2020, 22, 181.	3.5	15
189	A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2603-2610.	2.8	14
190	The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the United States: supplementary presentation. <i>Osteoporosis International</i> , 2017, 28, 3283-3284.	3.1	14
191	Is Rheumatoid Arthritis a Cardiovascular Risk Equivalent to Diabetes Mellitus?. <i>Arthritis Care and Research</i> , 2018, 70, 1694-1699.	3.4	14
192	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802.	2.0	14
193	Nonsteroidal Anti-Inflammatory Drugs. <i>Spine</i> , 1994, 19, 1530-1534.	2.0	13
194	Developing a bone mineral density test result letter to send to patients: a mixed-methods study. <i>Patient Preference and Adherence</i> , 2014, 8, 827.	1.8	13
195	Bone safety of low-dose glucocorticoids in rheumatic diseases. <i>Annals of the New York Academy of Sciences</i> , 2014, 1318, 55-64.	3.8	13
196	A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material. <i>Contemporary Clinical Trials Communications</i> , 2016, 4, 14-24.	1.1	13
197	Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 478-487.	2.8	13
198	Real-world bone turnover marker use: impact on treatment decisions and fracture. <i>Osteoporosis International</i> , 2021, 32, 831-840.	3.1	13

#	ARTICLE	IF	CITATIONS
199	Improving quality of care in osteoporosis: Opportunities and challenges. <i>Current Rheumatology Reports</i> , 2008, 10, 123-130.	4.7	12
200	Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients. <i>Pediatric Rheumatology</i> , 2016, 14, 49.	2.1	12
201	Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study. <i>Contemporary Clinical Trials</i> , 2016, 50, 106-115.	1.8	12
202	Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. <i>Arthritis Care and Research</i> , 2021, 73, 471-480.	3.4	12
203	Osteoporosis in the home health care setting: A window of opportunity?. <i>Arthritis and Rheumatism</i> , 2006, 55, 971-975.	6.7	11
204	Management of Osteoporosis Among Home Health and Long-Term Care Patients with a Prior Fracture. <i>Southern Medical Journal</i> , 2009, 102, 397-404.	0.7	11
205	Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. <i>Core Evidence</i> , 2010, 4, 25.	4.7	11
206	Prevention and Treatment of Bone Changes Associated with Exposure to Glucocorticoids. <i>Current Osteoporosis Reports</i> , 2013, 11, 341-347.	3.6	11
207	Effects of a DXA result letter on satisfaction, quality of life, and osteoporosis knowledge: a randomized controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 369.	1.9	11
208	Racial Differences and Disparities in Osteoporosis-related Bone Health. <i>Medical Care</i> , 2017, 55, 561-568.	2.4	11
209	A Qualitative Study of the Postoperative Pain Management Educational Needs of Total Joint Replacement Patients. <i>Pain Management Nursing</i> , 2019, 20, 345-351.	0.9	11
210	Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 449-460.	2.0	11
211	Balancing benefits and risks in the era of biologics. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1988397.	2.7	10
212	Race Plays a Role in the Knowledge, Attitudes, and Beliefs of Women with Osteoporosis. <i>Journal of Racial and Ethnic Health Disparities</i> , 2019, 6, 707-718.	3.2	10
213	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. <i>Journal of Orthopaedic Trauma</i> , 2020, 34, e125-e141.	1.4	10
214	Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1593-1601.	5.6	10
215	Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 11-18.	1.9	9
216	Systems-based approaches to osteoporosis and fracture care: policy and research recommendations from the workgroups. <i>Osteoporosis International</i> , 2011, 22, 495-500.	3.1	9

#	ARTICLE	IF	CITATIONS
217	Drug Treatment of Hyperuricemia to Prevent Cardiovascular Outcomes. American Journal of Cardiovascular Drugs, 2012, 12, 1-6.	2.2	9
218	The Safety of Low-Dose Glucocorticoids in Rheumatic Diseases: Results from Observational Studies. NeuroImmunoModulation, 2015, 22, 72-82.	1.8	9
219	Self-perception of fracture risk: what can it tell us?. Osteoporosis International, 2017, 28, 3495-3500.	3.1	9
220	Tools and Methods for Real-World Evidence Generation. Rheumatic Disease Clinics of North America, 2019, 45, 275-289.	1.9	9
221	A Randomized Internet-Based Pilot Feasibility and Planning Study of Cherry Extract and Diet Modification in Gout. Journal of Clinical Rheumatology, 2020, 26, 147-156.	0.9	9
222	Glucocorticoid-Induced Osteoporosis. , 2008, , 1135-1166.		9
223	COVID-19 vaccine uptake and vaccine hesitancy in rheumatic disease patients receiving immunomodulatory therapies in community practice settings. Arthritis and Rheumatology, 2022, 74, 1091-1092.	5.6	9
224	Regional Variation in the Denial of Reimbursement for Bone Mineral Density Testing Among US Medicare Beneficiaries. Journal of Clinical Densitometry, 2008, 11, 568-574.	1.2	8
225	Do physicians within the same practice setting manage osteoporosis patients similarly? Implications for implementation research. Osteoporosis International, 2009, 20, 1921-1927.	3.1	8
226	Improving osteoporosis care in high-risk home health patients through a high-intensity intervention. Contemporary Clinical Trials, 2012, 33, 206-212.	1.8	8
227	From Fracture Risk Prediction to Evaluating Fracture Patterns: Recent Advances in the Epidemiology of Osteoporosis. Current Rheumatology Reports, 2012, 14, 205-211.	4.7	8
228	Vascular Consequences of Hyperuricemia and Hypouricemia. Rheumatic Disease Clinics of North America, 2019, 45, 453-464.	1.9	8
229	Gout treatment: What is evidence-based and how do we determine and promote optimized clinical care?. Current Rheumatology Reports, 2005, 7, 242-249.	4.7	7
230	Use of health plan combined with registry data to predict clinical trial recruitment. Clinical Trials, 2014, 11, 96-101.	1.6	7
231	Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone mass. Osteoporosis International, 2014, 25, 317-324.	3.1	7
232	An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users. Journal of Rheumatology, 2015, 42, 1478-1483.	2.0	7
233	Activating Patients With a Tailored Bone Density Test Results Letter and Educational Brochure: the PAADRN Randomized Controlled Trial. Journal of Clinical Densitometry, 2017, 20, 464-471.	1.2	7
234	Allopurinol adherence and its predictors in gout: a national cohort study in US veterans. Lancet Rheumatology, The, 2020, 2, e281-e291.	3.9	7

#	ARTICLE	IF	CITATIONS
235	Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture. <i>Clinical Therapeutics</i> , 2020, 42, 1099-1107.e1.	2.5	7
236	Fractures and mortality in relation to different osteoporosis treatments. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 302-9.	0.8	7
237	Evaluating the effectiveness of a patient storytelling DVD intervention to encourage physician-patient communication about nonsteroidal anti-inflammatory drug (NSAID) use. <i>Patient Education and Counseling</i> , 2016, 99, 1837-1844.	2.2	6
238	The National Osteoporosis Foundation's methods and processes for developing position statements. <i>Archives of Osteoporosis</i> , 2016, 11, 22.	2.4	6
239	Editorial: Response to the American College of Physicians Osteoporosis Guideline, 2017 Update. <i>Arthritis and Rheumatology</i> , 2017, 69, 2097-2101.	5.6	6
240	Healthcare Providers' Recommendations for Physical Activity among US Arthritis Population: A Cross-Sectional Analysis by Race/Ethnicity. <i>Arthritis</i> , 2018, 2018, 1-9.	2.0	6
241	Design, analysis, power, and sample size calculation for three-phase interrupted time series analysis in evaluation of health policy interventions. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 826-841.	1.8	6
242	Machine learning approaches for the prediction of bone mineral density by using genomic and phenotypic data of 5130 older men. <i>Scientific Reports</i> , 2021, 11, 4482.	3.3	6
243	The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids. <i>Arthritis and Rheumatology</i> , 2022, 74, 604-611.	5.6	6
244	Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment. <i>Osteoporosis International</i> , 2020, 31, 1283-1290.	3.1	6
245	The Validity of Claims-Based Algorithms to Identify Serious Hypersensitivity Reactions and Osteonecrosis of the Jaw. <i>PLoS ONE</i> , 2015, 10, e0131601.	2.5	6
246	Short-term and long-term safety of glucocorticoids in rheumatoid arthritis. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2012, 70 Suppl 1, 21-5.	0.7	6
247	Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1136-1146.	2.8	6
248	Unbalanced regulation of over-the-counter analgesics: the lesser of two evils?. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 410-411.	1.9	5
249	Multimodal intervention to improve osteoporosis care in home health settings: results from a cluster randomized trial. <i>Osteoporosis International</i> , 2013, 24, 2555-2560.	3.1	5
250	Glucocorticoid-Induced Osteoporosis. , 2013, , 1191-1223.		5
251	The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. <i>Contemporary Clinical Trials</i> , 2016, 50, 238-244.	1.8	5
252	Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study. <i>Osteoporosis International</i> , 2017, 28, 2495-2503.	3.1	5

#	ARTICLE	IF	CITATIONS
253	Taking an Interdisciplinary Approach to Understanding and Improving Medication Adherence. <i>Journal of General Internal Medicine</i> , 2018, 33, 136-138.	2.6	5
254	Which factors predict discordance between a patient and physician on a gout flare?. <i>Rheumatology</i> , 2021, 60, 773-779.	1.9	5
255	Systemic glucocorticoids in rheumatology. , 2015, , 423-433.		5
256	What's new on the front-line of gout pharmacotherapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 453-464.	1.8	5
257	Evaluating and improving the quality of care in rheumatic disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 429-439.	1.4	4
258	Diet and exercise changes following bone densitometry in the Patient Activation After DXA Result Notification (PAADRN) study. <i>Archives of Osteoporosis</i> , 2018, 13, 4.	2.4	4
259	How to use bisphosphonates safely and optimally. <i>Rheumatology</i> , 2018, 57, 1875-1876.	1.9	4
260	A Performing Arts Intervention Improves Cognitive Dysfunction in 50 Hospitalized Older Adults. <i>Innovation in Aging</i> , 2018, 2, igy013.	0.1	4
261	Comparison of an interactive voice response system and smartphone application in the identification of gout flares. <i>Arthritis Research and Therapy</i> , 2019, 21, 160.	3.5	4
262	Imminent Fracture Risk: A Call to Action for Rheumatologists. <i>Arthritis Care and Research</i> , 2020, 72, 741-743.	3.4	4
263	Sex differences in osteoporosis self-efficacy among community-residing older adults presenting for DXA. <i>Osteoporosis International</i> , 2019, 30, 1033-1041.	3.1	4
264	Study design considerations for a large simple trial of bisphosphonates. <i>Current Opinion in Rheumatology</i> , 2013, 25, 517-523.	4.3	3
265	Challenges in Defining Quality of Care for Glucocorticoid-induced Osteoporosis: Defending Good Against Perfect. <i>Journal of Rheumatology</i> , 2013, 40, 1640-1642.	2.0	3
266	Evaluation of a "Just-in-Time" Nurse Consultation on Bone Health: A Pilot Randomized Controlled Trial. , 2017, 21, 16-112.		3
267	Just the FRAX: Management of Glucocorticoid-Induced Osteoporosis. <i>Gastroenterology</i> , 2018, 154, 748-750.	1.3	3
268	Characteristics of older adults using patient web portals to view their DXA results. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 187.	3.0	3
269	Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective study. <i>Archives of Osteoporosis</i> , 2020, 15, 32.	2.4	3
270	Reply to Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 996-997.	2.8	3

#	ARTICLE	IF	CITATIONS
271	Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis. <i>Osteoporosis International</i> , 2021, 32, 1879-1888.	3.1	3
272	Higher Serum Urate Levels Are Associated With an Increased Risk for Sudden Cardiac Death. <i>Journal of Rheumatology</i> , 2021, 48, 1745-1753.	2.0	3
273	Moving Career Development Upstream: Evaluation of a Course for Internal Medicine Trainees Contemplating Career Pathways in Academic Medicine. <i>Southern Medical Journal</i> , 2018, 111, 471-475.	0.7	3
274	Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1378-1385.	3.4	3
275	The prevalence of overtreatment of osteoporosis: results from the PAADRN trial. <i>Archives of Osteoporosis</i> , 2018, 13, 103.	2.4	2
276	Pragmatic Clinical Trials in Osteoporosis. <i>Current Osteoporosis Reports</i> , 2019, 17, 521-526.	3.6	2
277	Cardiovascular safety risks associated with gout treatments. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1143-1154.	2.4	2
278	Variation in serum urate levels in the absence of gout and urate lowering therapy. <i>BMC Rheumatology</i> , 2021, 5, 32.	1.6	2
279	Denosumab did not improve computerized tomography erosion scores when added to intensive urate-lowering therapy in gout: Results from a pilot randomized controlled trial. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1218-1223.	3.4	2
280	Tumor Necrosis Factor, Tuberculosis, Testing, and Treatment: Teeing Up the Questions. <i>Arthritis Care and Research</i> , 2013, 65, 1719-1721.	3.4	1
281	Socio-demographic differences in risk information seeking sources for non-steroidal anti-inflammatory drugs (NSAIDs). <i>International Journal of Medical Informatics</i> , 2016, 94, 222-227.	3.3	1
282	Glucocorticoid-Induced Osteoporosis: Update on Management. <i>Current Treatment Options in Rheumatology</i> , 2018, 4, 279-287.	1.4	1
283	The Contribution of Patient, Primary Care Physician, and Primary Care Clinic Factors to Good Bone Health Care. , 2021, 25, 1-3.		1
284	Systemic glucocorticoids in rheumatology. , 2011, , 495-503.e3.		1
285	Rofecoxib. <i>Drugs</i> , 1999, 58, 506-507.	10.9	0
286	Improving the quality of clinical care for patients with osteoporosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2006, 6, 641-645.	1.4	0
287	Is Two Better Than One? Combining Antiresorptive and Anabolic Osteoporosis Medications. <i>Current Osteoporosis Reports</i> , 2011, 9, 109-111.	3.6	0
288	FRIO529â€¦Comparative risks for serious infections associated with biologics in high risk rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A553.3-A554.	0.9	0

#	ARTICLE	IF	CITATIONS
289	The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trial. <i>Osteoporosis International</i> , 2017, 28, 3061-3066.	3.1	0
290	Validity, reliability, and responsiveness to change of the "Osteoporosis and You" knowledge scale. <i>Osteoporosis International</i> , 2017, 28, 3379-3388.	3.1	0
291	Reply. <i>Arthritis and Rheumatology</i> , 2019, 71, 1771-1772.	5.6	0
292	FRI0469...CHANGES IN DKK-1, SCLEROSTIN, AND RANKL SERUM LEVELS FOLLOWING DISCONTINUATION OF LONG-TERM DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN. , 2019, , .		0
293	Use of path modeling to inform a clinical decision support application to encourage osteoporosis medication use. <i>Research in Social and Administrative Pharmacy</i> , 2020, 17, 1267-1275.	3.0	0
294	Glucocorticoid-induced osteoporosis and Cushing's syndrome. , 2021, , 1103-1138.		0
295	The effects of a patient activation intervention on smoking and excessive drinking cessations: results from the PAADRN randomized controlled trial. <i>Osteoporosis International</i> , 2017, 28, 3055-3060.	3.1	0
296	SAT-519 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture Representative of Covered Commercial Insurance Enrollees. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
297	Identification of Gout Flares in Chief Complaint Text Using Natural Language Processing. <i>AMIA ... Annual Symposium proceedings</i> , 2020, 2020, 973-982.	0.2	0
298	Understanding Physicians' Perceptions of Patient-Identified Barriers to Osteoporosis Medication Initiation: A Cognitive Mapping Approach. <i>Risk Management and Healthcare Policy</i> , 0, Volume 15, 1293-1302.	2.5	0